Celltrion's Covid treatment found effective in Phase 2 trial

Home > Business > Industry

print dictionary print

Celltrion's Covid treatment found effective in Phase 2 trial

Celltrion’s CT-P59 was proven to speed up the recovery time for Covid-19 infection in a Phase 2 clinical trial. [YONHAP]

Celltrion’s CT-P59 was proven to speed up the recovery time for Covid-19 infection in a Phase 2 clinical trial. [YONHAP]

 
Celltrion’s Covid-19 treatment candidate has been proven to speed up the recovery time for the infected in a Phase 2 clinical trial, according to the drug maker speaking at an academic conference on Wednesday.
 
It would be the first coronavirus therapy developed in Korea.  
 
Those who received CT-P59, or regdanvimab, had a median recovery time of 5.4 days compared with 8.8 days among those who received a placebo, cutting about 3 days off the recovery time.
 
The candidate drug also reduced the possibility of cases worsening to the severe level, which requires hospitalization, by 54 percent.
 
For those aged over 50 with moderate symptoms, the likelihood shrank by 68 percent.
 
The tests were conducted on 327 patients last year with mild to moderate symptoms in Korea, Romania, Spain and the United States. Doses of 40 milligrams were administered.
 
The result, released through an electronic disclosure site ahead of the conference, also stated that no adverse effects had been reported during the test.
 
“The data demonstrate that CT-P59 could contribute to both a reduced time to clinical recovery, as well as a reduced proportion of patients who progress to a severe condition.” said Professor Eom Joong-Sik, Infectious Disease Division at Gil Medical Center of Gachon University in a statement.
 
“The treatment’s safety profile was comparable to that of placebo and generally well-tolerated. Therefore, it is anticipated that CT-P59 will positively contribute to the management and control of the current Covid-19 pandemic around the world,” he said.
 
With the optimistic result, the Songdo-based drug maker will go on with the third phase of trials. It submitted an application to obtain the conditional use permit for its treatment candidate last month.

 
The unit has been authorized to start Phase 3 clinical trials in Korea, Romania, the United States, Britain, Spain and Italy.  
 
The successful result was hinted at during a discussion at the National Assembly on Tuesday, where a senior official of Celltrion said that the candidate has been proven to show comparable or even better performance than competing drugs.
 
“We’ve confirmed that [the CT-P59] has shown either comparable or better efficacy than antibody treatments including those from Eli Lilly and Regeneron,” said Kwon Ki-sung, head of the research and development department of Celltrion, during the meeting.
 
“Empirical data has shown that the drug is effective in holding the virus at bay and keeping the patient from developing severe respiratory conditions. We’re hoping to get it approved by the Ministry of Food and Drug Safety within the month,” he said.
 
Kwon also added that the treatment candidate is more effective when taken in the early stage.
 
Whereas the Phase 2 tests focused on verifying the treatment candidate’s ability to reduce the recovery period, Phase 3 trials will observe whether it is effective in reducing the portion of patients whose conditions would have worsened and required hospital care or oxygen therapy.
 
Gilead Sciences’ remdesivir is the only Covid-19 treatment approved for use in Korea.
 
BY PARK EUN-JEE   [park.eunjee@joongang.co.kr]

More in Industry

Live commerce, perfect for the pandemic, is all the rage

Amcham head warns tax, overregulation are holding Korea back

Hyundai Motor expected to see big profit boost this year

PoongLim syringes may increase Covid vaccine efficiency by 20%

FKI head congratulates Biden, calls for 'restoration of open trade'

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now